This forum post is hidden because you have chosen to ignore Dr. K. Ashutosh. Show Details
This forum post is hidden because you have submitted an abuse report against it. Show Details
An orally active drug that blocks the activity of the molecule PI3Kgamma at the first signs of disease onset. The drug even suppressed the development of EAE and reversed clinical signs of the disease. By blocking PI3Kgamma, we can reduce the activation of self-reactive immune cells, reduce the release of inflammation-inducing molecules from immune cells, and also result in a dramatic reduction in the movement of immune cells into the central nervous system.
Future therapies for MS might target this molecule, which could very specifically dampen the damaging inflammation in the central nervous system.